@article{1e47d7fc8cae46878a7e86d4e3e2e0d3,
title = "Weight-Based Dosing of Pembrolizumab Every 6 Weeks in the Time of COVID-19",
author = "Goldstein, {Daniel A.} and Ratain, {Mark J.} and Saltz, {Leonard B.}",
note = "Funding Information: reported institutional research funding from Merck and personal fees from VIVIO Health. Dr Ratain reported personal fees from Aurobindo Pharma, Apotex, Ascentage Pharma, Teva Pharmaceutical Industries, Cyclacel Pharmaceuticals, Celltrion, Breckenridge Pharmaceutical, Par Pharmaceuticals, Roxane Laboratories, Aptevo Therapeutics, Accord Healthcare, Actavis, Amerigen Pharmaceuticals, Argentum Pharmaceuticals, BPI Labs, Belcher Pharmaceuticals, Dr Reddy{\textquoteright}s Laboratories, Fresenius Kabi, Glenmark Pharmaceuticals, Hetero, Mylan, Sandoz, Pneuma Respiratory, and Shionogi; grants from AbbVie, Dicerna Pharmaceuticals, Genentech, and Xencor; and other fees from BeiGene; has a patent to US6395481B1 issued, licensed, and with royalties paid, a patent to EP1629111B1 issued, licensed, and with royalties paid, a patent to US8877723B2 issued, and a patent to US9617583B2 issued; and is director and treasurer of the Value in Cancer Care Consortium. No other disclosures were reported.",
year = "2020",
doi = "10.1001/jamaoncol.2020.2493",
language = "אנגלית",
volume = "6",
pages = "1694--1695",
journal = "JAMA Oncology",
issn = "2374-2437",
publisher = "American Medical Association",
number = "11",
}
